Evidence map›Paper›PMID 35222708›Full record

ArticleExperimental and therapeutic medicine2022

miR-146b-5p promotes colorectal cancer progression by targeting TRAF6.

Liangpan Shi, Yibin Su, Zhihua Zheng, Jinyu Qi, Weidong Wang, Cunchuan Wang

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.International journal of molecular sciences · 2024
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Role of NRF2 in Ovarian Cancer.Antioxidants (Basel, Switzerland) · 2022
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Liangpan ShiDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China.
Yibin SuDepartment of Gastrointestinal Surgery, The First Hospital of Quanzhou Affiliated of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China.
Zhihua ZhengDepartment of Gastrointestinal Surgery, The First Hospital of Quanzhou Affiliated of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China.
Jinyu QiDepartment of Gastrointestinal Surgery, The First Hospital of Quanzhou Affiliated of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China.
Weidong WangDepartment of Gastrointestinal Surgery, The First Hospital of Quanzhou Affiliated of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China.
Cunchuan WangDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China.
Fujian Medical University · CNFirst Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence highlights the multiple roles of microRNAs (miRs) in the tumorigenesis of colorectal cancer (CRC); however, the molecular mechanism, particularly the target of miR-146b-5p in CRC has not been fully elucidated. The present study aimed to elucidate the influence of miR-146b-5p via regulating tumor necrosis factor receptor-associated factor 6 (TRAF6) in CRC. The expression levels of miR-146b-5p and TRAF6 in CRC tissue and cells were determined by reverse transcription quantitative PCR and western blotting. Binding between miR-146b-5p and TRAF6 was examined using a dual luciferase reporter gene assay. The impact of miR-146b-5p and TRAF6 on proliferation and migration of CRC cells was determined using Cell Counting Kit-8 and Transwell assays, respectively. An animal model of CRC was established to determine the carcinogenic effect of the miR-146b-5p-TRAF6 axis. The results demonstrated that miR-146b-5p was highly expressed in CRC tissue samples compared with in normal adjacent tissue samples and in CRC cells compared with in the normal NCM460 cell line, whereas TRAF6 was expressed at low levels. Overexpression of miR-146b-5p decreased TRAF6 expression in CRC HT29 and SW620 cells. miR-146b-5p targeted and inhibited TRAF6 expression in CRC cells. Furthermore, transfection with a miR-146b-5p mimic promoted the proliferation, migration and invasion of CRC cells and tumor growth; however, these effects were abolished by TRAF6 overexpression. Transfection with a miR-146b-5p inhibitor suppressed the proliferation of CRC cells. Taken together, the results from the present study demonstrated that miR-146b-5p could enhance the initiation and tumorigenesis of CRC by targeting TRAF6. These results will help elucidate the mechanisms underlying CRC development and will facilitate the development of targeted therapy for CRC.

Indexed as

colorectal cancermicroRNA-146b-5ptumorigenesistumor necrosis factor receptor-associated factor 6

Identifiers

PMID35222708
PMCPMC8815033
OpenAlexW4210833860

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.